menu
Intellia Therapeutics Head office building

Press Releases

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where
Read More

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapy Presentation to include data supporting fixed dose selection in the ongoing single-dose expansion cohort of polyneuropathy
Read More

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001 resulted in rapid, deep and sustained reduction in disease-causing protein Interim readout showed treatment with NTLA-2001 at 1.0
Read More

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

CAMBRIDGE, Mass. , May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji , R.Ph., to its board of
Read More

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading  T cells and deployable for TCR-T and CAR-T cell therapy Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of
Read More

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass. , April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financial results and
Read More

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia

NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia CAMBRIDGE, Mass. , March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Decision Relating to CRISPR/Cas9 Genome Editing Technology in Eukaryotic Cells

Background In May 2012, the Regents of University of California, University of Vienna, and Emmanuelle Charpentier (collectively, “CVC”) filed a patent application for their CRISPR/Cas9 genome editing technology. The CVC team led by Drs. Jennifer Doudna and Emmanuelle Charpentier promptly brought
Read More

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia

NTLA-5001 is a novel investigational T cell receptor (TCR)-T cell therapy which leverages Intellia’s proprietary cell engineering platform    NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen frequently found in acute myeloid leukemia (AML) and other hematologic and
Read More

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months NTLA-2001 was generally well tolerated
Read More
RSS FEEDS
PRINT PAGE